Search Results - "Reingold, S"

Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

“…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
Get full text

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population by Szczepaniak, Lidia S, Nurenberg, Pamela, Leonard, David, Browning, Jeffrey D, Reingold, Jason S, Grundy, Scott, Hobbs, Helen H, Dobbins, Robert L

“…Despite the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), the criteria used to diagnose the disorder remain poorly defined. Localized…”
Get more information

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment by Fischer, J S, Rudick, R A, Cutter, G R, Reingold, S C

“…Clinical outcome assessment in Multiple Sclerosis (MS) is challenging due to the diversity and fluctuating nature of MS symptoms. Traditional clinical scales…”
Get full text

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group by André, T., Vernerey, D., Im, S.A., Bodoky, G., Buzzoni, R., Reingold, S., Rivera, F., McKendrick, J., Scheithauer, W., Ravit, G., Fountzilas, G., Yong, W.P., Isaacs, R., Österlund, P., Liang, J.T., Creemers, G.J., Rakez, M., Van Cutsem, E., Cunningham, D., Tabernero, J., de Gramont, A.

“…The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to…”
Get full text

The role of magnetic resonance techniques in understanding and managing multiple sclerosis by MILLER, D. H, GROSSMAN, R. I, REINGOLD, S. C, MCFARLAND, H. F

“…Magnetic resonance (MR) techniques have had a major impact in the last 10-15 years in understanding and managing multiple sclerosis. This review summarizes the…”
Get full text

Defining the clinical course of multiple sclerosis : Results of an international survey by LUBLIN, F. D, REINGOLD, S. C

Get full text

Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method by Reingold, Jason S, McGavock, Jonathan M, Kaka, Shaheen, Tillery, Tommy, Victor, Ronald G, Szczepaniak, Lidia S

“…The primary aim of this investigation was to determine the reliability and sensitivity of 1H magnetic resonance spectroscopy (1H-MRS) as a method for…”
Get more information

Vision and vision-related outcome measures in multiple sclerosis by Balcer, Laura J, Miller, David H, Reingold, Stephen C, Cohen, Jeffrey A

“…Visual impairment is a key manifestation of multiple sclerosis. Acute optic neuritis is a common, often presenting manifestation, but visual deficits and…”
Get full text

Association of HIV Infection and HIV/HCV Coinfection With C-Reactive Protein Levels: The Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study by Reingold, Jason S, Wanke, Christine, Kotler, Donald P, Lewis, Cora E, Tracy, Russell, Heymsfield, Steven, Tien, Phyllis C, Bacchetti, Peter, Scherzer, Rebecca, Grunfeld, Carl, Shlipak, Michael G

“…OBJECTIVE:Inflammation is a potential mechanism to explain the accelerated atherosclerosis observed in HIV- and hepatitis C virus (HCV)-infected persons. We…”
Get full text

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials by Rudick, R A, Cutter, G, Reingold, S

“…With the advent and widespread use of partially effective disease modifying drug therapies for multiple sclerosis (MS), future clinical trials will undoubtedly…”
Get full text

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses by Petkau, J, Reingold, SC, Held, U, Cutter, GR, Fleming, TR, Hughes, MD, Miller, DH, McFarland, HF, Wolinsky, JS

“…Background Magnetic resonance imaging (MRI) of lesions in the brain may be the best current candidate for a surrogate biological marker of clinical outcomes in…”
Get full text

The challenge of follow-on biologics for treatment of multiple sclerosis by REINGOLD, S. C, STEINER, J. P, POLMAN, C. H, COHEN, J. A, FREEDMAN, M. S, KAPPOS, L, THOMPSON, A. J, WOLINSKY, J. S

“…Intellectual property protections for biologic medicinals for multiple sclerosis (MS) are beginning to expire, opening the possibility of development,…”
Get full text

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment by Polman, C H, Reingold, S C, Barkhof, F, Calabresi, P A, Clanet, M, Cohen, J A, Cutter, G R, Freedman, M S, Kappos, L, Lublin, F D, McFarland, H F, Metz, L M, Miller, A E, Montalban, X, O'Connor, P W, Panitch, H, Richert, J R, Petkau, J, Schwid, S R, Sormani, M P, Thompson, A J, Weinshenker, B G, Wolinsky, J S

“…The increasing number of established effective therapies for relapsing multiple sclerosis (MS) and emerging consensus for early treatment raise practical…”
Get full text

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis by McDonald, W. Ian, Compston, Alistair, Edan, Gilles, Goodkin, Donald, Hartung, Hans-Peter, Lublin, Fred D., McFarland, Henry F., Paty, Donald W., Polman, Chris H., Reingold, Stephen C., Sandberg-Wollheim, Magnhild, Sibley, William, Thompson, Alan, Van Den Noort, Stanley, Weinshenker, Brian Y., Wolinsky, Jerry S.

“…The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of…”
Get full text

The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era by McFarland, H F, Reingold, S C

“…Due to past success in testing and gaining regulatory approval for a variety of therapies in multiple sclerosis (MS), the conduct of future clinical trials has…”
Get full text

Stem cell therapy in multiple sclerosis: promise and controversy by Duncan, ID, Goldman, S, Macklin, WB, Rao, M, Weiner, LP, Reingold, SC

“…Stem cells offer the potential for regeneration of lost tissue in neurological disease, including multiple sclerosis (MS). Their development in vitro and their…”
Get full text

Revised estimate of the prevalence of multiple sclerosis in the United States by Anderson, D W, Ellenberg, J H, Leventhal, C M, Reingold, S C, Rodriguez, M, Silberberg, D H

“…Using three adjustments, we have revised a 1976 prevalence count for multiple sclerosis in the United States. The adjustments were made to data from a US…”
Get more information

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis by Whitaker, J N, McFarland, H F, Rudge, P, Reingold, S C

“…The feasibility and precision of clinical trials for the treatment of MS must be improved. Subsequent to the approval by the Food and Drug Administration of…”
Get more information

Proof of concept studies for tissue-protective agents in multiple sclerosis by Mehta, LR, Schwid, SR, Arnold, DL, Cutter, GR, Aradhye, S, Balcer, LJ, Calabresi, PA, Cohen, JA, Cole, PE, Glanzman, R, Goelz, S, Inglese, M, Kapoor, R, Kappos, L, Kreitman, R, Lublin, FD, Mann, A, Marrie, RA, O'Looney, P, Polman, CH, Ravina, BM, Reingold, SC, Richert, JR, Sandrock, AW, Waubant, E

“…Background There is considerable interest in tissue-protective treatments for multiple sclerosis (MS). Methods and Objectives We convened a group of MS…”
Get full text

Neonatal Left Pulmonary Artery Occlusion and Postinfarction Cysts of the Left Lung: Cause and Effect? by Lytrivi, I., Reingold, S., Ramaswamy, P.

Get full text